Albendazole and Ovarian Cancer: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Albendazole and Ovarian Cancer: Latest Research 2026

This page summarizes the current state of scientific research on Albendazole in the context of Ovarian Cancer as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your gynecologic oncologist for personalized guidance.

Compound Overview

Albendazole (Antiparasitic / Benzimidazole) — FDA-approved for neurocysticercosis and hydatid disease; not approved for cancer

Mechanism of action: Inhibits tubulin polymerization; metabolized to active sulfoxide form; activates apoptotic pathways

Current evidence level: Preclinical + early clinical data; studied alongside chemotherapy

2026 Research Landscape

Research has directly examined Albendazole in Ovarian Cancer, making this a field with active scientific interest.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Albendazole affects the biological pathways involved in Ovarian Cancer progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Clinical trials: Phase I/II investigations examining Albendazole in Ovarian Cancer patients are ongoing or recently completed

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Albendazole[tiab]) AND (Ovarian Cancer[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Albendazole keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Albendazole + Ovarian Cancer research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Ovarian Cancer patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Albendazole for Ovarian Cancer?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Albendazole Ovarian Cancer' filtered to the last 2 years. The current evidence level is: Preclinical + early clinical data; studied alongside chemotherapy.

Are there any 2025-2026 clinical trials for Albendazole in Ovarian Cancer?

Check ClinicalTrials.gov with 'Albendazole' as intervention and 'Ovarian Cancer' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your gynecologic oncologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Albendazole in Ovarian Cancer changed recently?

The field evolves rapidly. The current evidence classification is: Preclinical + early clinical data; studied alongside chemotherapy. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.